Praxis Precision Medicines to Present at 2022 Wedbush PacGrow Healthcare Conference

BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in the Got My Mind Set On You Advancing Novel Epilepsy Targets panel at the 2022 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 10, 2022 at 12:35 p.m.

Metadata

Provider:

GlobeNewswire, Inc.

Retrieved on:

Wednesday, August 3, 2022

Information

Tags:

Event, Epilepsy, Brain, Media, Investor, Lists of diseases, Praxis, CNS, LinkedIn, Central nervous system disease, GLOBE, Conference, Central nervous system, Twitter, Webcast, Movement disorders, NASDAQ, Pharmaceutical industry

Geotags:

BOSTON, MA, US

Organisation:

PRAXIS PRECISION MEDICINES, INC.

Summary

Key Points:

BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in the Got My Mind Set On You Advancing Novel Epilepsy Targets panel at the 2022 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 10, 2022 at 12:35 p.m.
A replay of the webcast will be available on Praxis website for 30 days following the event.
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance.
Praxis has established a broad portfolio with multiple programs, including product candidates across movement disorders, epilepsy and psychiatric disorders, with three clinical-stage product candidates.

BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in the “Got My Mind Set On You – Advancing Novel Epilepsy Targets” panel at the 2022 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 10, 2022 at 12:35 p.m. ET.

The panel chat will be available via live webcast through the Events & Presentations page of the Investors + Media section of the company’s website at www.praxismedicines.com. A replay of the webcast will be available on Praxis’ website for 30 days following the event.

About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying insights from genetic epilepsies to both rare and more prevalent neurological disorders, using our understanding of shared biological targets and circuits in the brain. Praxis has established a broad portfolio with multiple programs, including product candidates across movement disorders, epilepsy and psychiatric disorders, with three clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on LinkedIn and Twitter.

Investor Contact:
Alex Kane
Praxis Precision Medicines
[email protected]
617-300-8481

Media Contact:
Ian Stone
Canale Communications
[email protected]
619-849-5388